Short answer
Bicara Therapeutics Inc. (BCAX) filed an 8-K current report with the SEC on July 28, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). Kiran Mazumdar-Shaw resigns July 28, 2026 without reported disagreement, removing one Board and governance committee member.
Bicara Therapeutics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Kiran Mazumdar-Shaw resigns July 28, 2026 without reported disagreement, removing one Board and governance committee member
- Jeremy Bender and Christy Oliger appointed independent directors, expanding Board size from nine to ten
- Each new director receives a 38,950-share initial stock option plus cash compensation under the director policy
- New Launch Readiness Committee targets commercialization strategy and launch execution, signaling heightened preparation for product launch
- Bender joins Audit Committee; Oliger joins Nominating and Governance Committee, strengthening independent oversight mapping
Item 7.01 · Regulation FD Disclosure
- Board appointments of Jeremy Bender and Christy Oliger announced
- Leadership additions may broaden board expertise and support strategic oversight
- Exhibit 99.1 contains the company’s press release and appointment details
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Bicara Therapeutics Inc. 8-K filings
Get the next BCAX 8-K as it lands
Follow BCAX for push alerts, or ask the research agent what this filing means.